N-linked glycosylation of SV2 is required for binding and uptake of botulinum neurotoxin A

Nature Structural and Molecular Biology

Volumn 23, Issue 7, 2016, Pages 656-662

  Yao, Guorui ^a   Zhang, Sicai ^b,c   Mahrhold, Stefan ^d   Lam, Kwok Ho ^a   Stern, Daniel ^e   Bagramyan, Karine ^f   Perry, Kay ^g   Kalkum, Markus ^f   Rummel, Andreas ^d   Dong, Min ^b,c   Jin, Rongsheng ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e ROBERT KOCH INSTITUTE   (Germany)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN A1; GLYCAN; MEMBRANE PROTEIN; NEUTRALIZING ANTIBODY; SYNAPTIC VESICLE GLYCOPROTEIN 2 PROTEIN; UNCLASSIFIED DRUG; ANTIDOTE; HYBRID PROTEIN; MONOCLONAL ANTIBODY; NERVE PROTEIN; PROTEIN BINDING; SV2C PROTEIN, HUMAN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANISOTROPY; ANTIGEN BINDING; ARTICLE; BRAIN CELL; CONTROLLED STUDY; CRYSTAL STRUCTURE; DEGLYCOSYLATION; EMBRYO; FEMALE; GLYCOSYLATION; HOST PATHOGEN INTERACTION; HYDROGEN BOND; MOTOR END PLATE; MOUSE; NERVE ENDING; NEUROTOXICITY; NEUROTROPISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; RAT; RECEPTOR BINDING; STEREOSPECIFICITY; WILD TYPE; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; CLOSTRIDIUM BOTULINUM; ESCHERICHIA COLI; GENE EXPRESSION; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; MOLECULAR CLONING; MOLECULAR MODEL; PATHOGENICITY; PROTEIN DOMAIN; PROTEIN PROCESSING; PROTEIN SECONDARY STRUCTURE; TRANSPORT AT THE CELLULAR LEVEL; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIDOTES; BINDING SITES; BIOLOGICAL TRANSPORT; BOTULINUM TOXINS, TYPE A; CLONING, MOLECULAR; CLOSTRIDIUM BOTULINUM; CRYSTALLOGRAPHY, X-RAY; ESCHERICHIA COLI; GENE EXPRESSION; GLYCOSYLATION; HEK293 CELLS; HUMANS; MEMBRANE GLYCOPROTEINS; MODELS, MOLECULAR; NERVE TISSUE PROTEINS; PROTEIN BINDING; PROTEIN DOMAINS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, SECONDARY; RECOMBINANT FUSION PROTEINS;

EID: 84977603945     PISSN: 15459993     EISSN: 15459985     Source Type: Journal    
DOI: 10.1038/nsmb.3245     Document Type: Article

References (45)

1. Montecucco, C. How do tetanus and botulinum neurotoxins bind to neuronal membranes? Trends Biochem. Sci. 11, 314-317 (1986).
2. Montecucco, C., Rossetto, O. & Schiavo, G. Presynaptic receptor arrays for clostridial neurotoxins. Trends Microbiol. 12, 442-446 (2004).
3. Rummel, A. Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity. Curr. Top. Microbiol. Immunol. 364, 61-90 (2013).
4. Dong, M. et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 312, 592-596 (2006).
5. Mahrhold, S., Rummel, A., Bigalke, H., Davletov, B. & Binz, T. The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett. 580, 2011-2014 (2006).
6. Dong, M. et al. Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol. Biol. Cell 19, 5226-5237 (2008).
7. Peng, L., Tepp, W.H., Johnson, E.A. & Dong, M. Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors. PLoS Pathog. 7, e1002008 (2011).
8. Rummel, A. et al. Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation-dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor. J. Neurochem. 110, 1942-1954 (2009).
9. Fu, Z., Chen, C., Barbieri, J.T., Kim, J.J. & Baldwin, M.R. Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F. Biochemistry 48, 5631-5641 (2009).
10. Benoit, R.M. et al. Structural basis for recognition of synaptic vesicle protein 2C by botulinum neurotoxin A. Nature 505, 108-111 (2014).
11. Chai, Q. et al. Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature 444, 1096-1100 (2006).
12. Jin, R., Rummel, A., Binz, T. & Brunger, A.T. Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature 444, 1092-1095 (2006).
13. Janz, R. & Südhof, T.C. SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family. Neuroscience 94, 1279-1290 (1999).
14. Helenius, A. & Aebi, M. Intracellular functions of N-linked glycans. Science 291, 2364-2369 (2001).
15. Rummel, A., Mahrhold, S., Bigalke, H. & Binz, T. The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol. Microbiol. 51, 631-643 (2004).
16. Pirazzini, M., Rossetto, O., Bolognese, P., Shone, C.C. & Montecucco, C. Double anchorage to the membrane and intact inter-chain disulfide bond are required for the low pH induced entry of tetanus and botulinum neurotoxins into neurons. Cell. Microbiol. 13, 1731-1743 (2011).
17. Swiech, K., Picanço-Castro, V. & Covas, D.T. Human cells: new platform for recombinant therapeutic protein production. Protein Expr. Purif. 84, 147-153 (2012).
18. Croset, A. et al. Differences in the glycosylation of recombinant proteins expressed in HEK and CHO cells. J. Biotechnol. 161, 336-348 (2012).
19. Bigalke, H. & Rummel, A. Botulinum neurotoxins: qualitative and quantitative analysis using the mouse phrenic nerve hemidiaphragm assay (MPN). Toxins (Basel) 7, 4895-4905 (2015).
20. Strotmeier, J. et al. Identification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin A. FEBS Lett. 588, 1087-1093 (2014).
21. Rossetto, O., Pirazzini, M. & Montecucco, C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat. Rev. Microbiol. 12, 535-549 (2014).
22. Barash, J.R. & Arnon, S.S. A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. J. Infect. Dis. 209, 183-191 (2014).
23. Gonzalez-Escalona, N. et al. Draft genome sequence of bivalent Clostridium botulinum strain IBCA10-7060, encoding botulinum neurotoxin B and a new FA mosaic type. Genome Announc. 2, e01275-14 (2014).
24. Kalb, S.R. et al. Functional characterization of botulinum neurotoxin serotype H as a hybrid of known serotypes F and A (BoNT F/A). Anal. Chem. 87, 3911-3917 (2015).
25. Maslanka, S.E. et al. A novel Botulinum toxin, previously reported as serotype H, has a hybrid structure of known serotypes A and F that is neutralized with serotype A antitoxin. J. Infect. Dis. 213, 379-385 (2016).
26. Fan, Y. et al. Immunological characterization and neutralizing ability of monoclonal antibodies directed against botulinum neurotoxin type H. J. Infect. Dis. 213, 1606-1614 (2016).
27. Kull, S. et al. Isolation and functional characterization of the novel Clostridium botulinum neurotoxin A8 subtype. PLoS One 10, e0116381 (2015).
28. Whitemarsh, R.C. et al. Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro. Infect. Immun. 81, 3894-3902 (2013).
29. Garcia-Rodriguez, C. et al. Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat. Biotechnol. 25, 107-116 (2007).
30. Nayak, S.U. et al. Safety and pharmacokinetics of XOMA 3AB, a novel mixture of three monoclonal antibodies against botulinum toxin A. Antimicrob. Agents Chemother. 58, 5047-5053 (2014).
31. Skehel, J.J. & Wiley, D.C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 69, 531-569 (2000).
32. Rouvinski, A. et al. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature 520, 109-113 (2015).
33. Garces, F. et al. Structural evolution of glycan recognition by a family of potent HIV antibodies. Cell 159, 69-79 (2014).
34. Kong, L. et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat. Struct. Mol. Biol. 20, 796-803 (2013).
35. Luca, V.C. et al. Structural biology: structural basis for Notch1 engagement of Delta-like 4. Science 347, 847-853 (2015).
36. Laskowski, R.A. & Swindells, M.B. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model. 51, 2778-2786 (2011).
37. Stenmark, P., Dupuy, J., Imamura, A., Kiso, M. & Stevens, R.C. Crystal structure of botulinum neurotoxin type A in complex with the cell surface co-receptor GT1b-insight into the toxin-neuron interaction. PLoS Pathog. 4, e1000129 (2008).
38. Matsumiya, S. et al. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J. Mol. Biol. 368, 767-779 (2007).
39. Kabsch, W. Xds. Acta Crystallogr. D Biol. Crystallogr. 66, 125-132 (2010).
40. McCoy, A.J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
41. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).
42. Potterton, E., Briggs, P., Turkenburg, M. & Dodson, E. A graphical user interface to the CCP4 program suite. Acta Crystallogr. D Biol. Crystallogr. 59, 1131-1137 (2003).
43. Brünger, A.T. Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. Nature 355, 472-475 (1992).
44. Chen, V.B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12-21 (2010).
45. Myszka, D.G. Improving biosensor analysis. J. Mol. Recognit. 12, 279-284 (1999).